Jeffrey Dunn Sells 20,000 Shares of SiBone (NASDAQ:SIBN) Stock

SiBone (NASDAQ:SIBN) Director Jeffrey Dunn sold 20,000 shares of SiBone stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $18.46, for a total value of $369,200.00. Following the completion of the sale, the director directly owned 16,057 shares in the company, valued at $296,412.22. This represents a 55.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

SiBone Stock Up 0.6%

NASDAQ SIBN opened at $18.14 on Friday. The business has a fifty day moving average price of $16.53 and a 200 day moving average price of $15.14. The company has a debt-to-equity ratio of 0.20, a quick ratio of 8.34 and a current ratio of 9.15. The company has a market cap of $804.51 million, a P/E ratio of -53.35 and a beta of 0.66. SiBone has a one year low of $11.48 and a one year high of $21.89.

SiBone (NASDAQ:SIBN) last released its earnings results on Monday, August 3rd. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.06. The business had revenue of $56.01 million during the quarter, compared to analyst estimates of $55.34 million. SiBone had a negative net margin of 6.85% and a negative return on equity of 8.23%. Research analysts anticipate that SiBone will post -0.4 EPS for the current fiscal year.

Hedge Funds Weigh In On SiBone

A number of institutional investors have recently bought and sold shares of the company. Versant Capital Management Inc boosted its holdings in SiBone by 102.9% in the 2nd quarter. Versant Capital Management Inc now owns 1,749 shares of the company’s stock valued at $29,000 after purchasing an additional 887 shares during the last quarter. Bank of America Corp DE increased its holdings in shares of SiBone by 8.7% during the 1st quarter. Bank of America Corp DE now owns 419,473 shares of the company’s stock worth $5,298,000 after buying an additional 33,688 shares during the last quarter. ADAR1 Capital Management LLC acquired a new stake in shares of SiBone during the 1st quarter worth approximately $159,000. Quantinno Capital Management LP raised its position in shares of SiBone by 58.2% during the 1st quarter. Quantinno Capital Management LP now owns 29,475 shares of the company’s stock valued at $372,000 after buying an additional 10,848 shares during the period. Finally, First Light Asset Management LLC raised its position in shares of SiBone by 6.4% during the 1st quarter. First Light Asset Management LLC now owns 5,353,190 shares of the company’s stock valued at $67,611,000 after buying an additional 320,286 shares during the period. 98.11% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on SIBN shares. TD Cowen upped their price objective on shares of SiBone from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Tuesday. UBS Group raised their target price on shares of SiBone from $24.00 to $25.00 and gave the stock a “buy” rating in a research note on Tuesday. Truist Financial restated a “buy” rating and set a $23.00 target price (up from $21.00) on shares of SiBone in a report on Tuesday. Wall Street Zen lowered SiBone from a “buy” rating to a “hold” rating in a research report on Saturday, April 18th. Finally, Weiss Ratings cut SiBone from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $24.29.

SiBone Company Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.